Ghassemi Fariba, Makateb Ali, Dastjani Farahani Afsar, Mahmoudi Alireza, Bazvand Fatemeh
Department of Ophthalmology, Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Ophthalmol. 2022 Jul 31;2022:5177401. doi: 10.1155/2022/5177401. eCollection 2022.
To assess possible neurodevelopmental delay (NDD) following intravitreal antivascular endothelial growth factor (VEGF) injection in neonates with retinopathy of prematurity (ROP).
In this retrospective cohort study, neurodevelopmental milestones in patients with a history of ROP and intravitreal bevacizumab (IVB) injection were compared with other gestations that received either no treatment or only a laser for treatment.
One hundred and twenty-five neonates (of 59 multi-gestation pregnancies) were included in this study (with the range of age 1-7 years old). Sixty-five (51.18%) were male and sixty-two (48.81%) were female. The mean gestational age (GA) and birth weight of all neonates were 29.69 ± 1.57 weeks (ranges: 26-33 weeks) and 1312.50 ± 269.33 grs (ranges: 730-2100 grs). None of the neurodevelopmental outcomes were statistically different when two subgroups in group (IVB vs. control) were compared. None of the differences between IVB and laser treated subgroups is statistically significant, except for "reaching for toys," which was delayed in the laser treated subgroup (6.6 ± 2.5 and 6.9 ± 2.5 months in IVB and laser treated subgroups, respectively).
In neonates with ROP, there is no linear correlation between intravitreal anti-VEGF injection and neurodevelopmental delay.
评估玻璃体内注射抗血管内皮生长因子（VEGF）对早产儿视网膜病变（ROP）新生儿可能产生的神经发育延迟（NDD）。
在这项回顾性队列研究中，将有ROP病史并接受玻璃体内注射贝伐单抗（IVB）的患者的神经发育里程碑与未接受治疗或仅接受激光治疗的其他孕周患者进行比较。
本研究纳入了125例新生儿（来自59例多胎妊娠）（年龄范围为1至7岁）。65例（51.18%）为男性，62例（48.81%）为女性。所有新生儿的平均胎龄（GA）和出生体重分别为29.69±1.57周（范围：26至33周）和1312.50±269.33克（范围：730至2100克）。比较组内两个亚组（IVB组与对照组）时，神经发育结局均无统计学差异。IVB组和激光治疗亚组之间除“伸手够玩具”外，其他差异均无统计学意义，激光治疗亚组“伸手够玩具”延迟（IVB组和激光治疗亚组分别为6.6±2.5个月和6.9±2.5个月）。
在患有ROP的新生儿中，玻璃体内注射抗VEGF与神经发育延迟之间不存在线性相关性。
